Billionaire Paulsen's PolyPeptide Group plans Swiss IPO to fund growth
3 Min Read ZURICH (Reuters) - PolyPeptide Group, controlled by a foundation of Swedish billionaire adventurer Frederik Paulsen Jr., said Monday it plans to list a 40% stake on the Swiss stock exchange to finance the contract drug maker’s growth. The company, which makes ingredients for U.S.-based Novavax Inc’s, COVID-19 vaccine candidate, plans to list in the second quarter. It plans to place existing shares and a primary offering, with some proceeds to go for potential acquisitions. PolyPeptide is eyeing “adjacent” business areas, in not only oligonucleotides that can be used in gene...
Source: reuters.com